Chief Operating Officer Lecault Veronique exercised 83,334 shares at a strike of $0.19, increasing direct ownership by 4% to 2,123,456 units (SEC Form 4)

$ABCL
Pharmaceuticals and Biotechnology
Health Care
Get the next $ABCL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lecault Veronique

(Last) (First) (Middle)
C/O ABCELLERA BIOLOGICS INC
2215 YUKON STREET

(Street)
VANCOUVER A1

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/21/2024 M V 83,334 A $0.188 2,123,456 D
Common Shares 61,580 I By spouse
Common Shares 7,155,008 I See Footnote(1)
Common Shares 273,630 I See Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share option (right to buy) $0.188 06/21/2024 M V 83,334 (3) 03/23/2027 Common Shares 83,334 $0 3,829,771 D
Explanation of Responses:
1. These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
2. These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
3. The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks:
Tryn Stimart, attorney-in-fact 06/24/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ABCL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABCL

DatePrice TargetRatingAnalyst
8/20/2024Buy → Hold
The Benchmark Company
2/22/2024$9.00Hold → Buy
The Benchmark Company
12/5/2023$6.00Overweight
KeyBanc Capital Markets
11/6/2023Buy → Hold
The Benchmark Company
10/13/2023$20.00Overweight
Piper Sandler
2/28/2023Outperform
Cowen
12/15/2022$30.00Buy
Goldman
11/16/2022$29.00Buy
Truist
More analyst ratings

$ABCL
Press Releases

Fastest customizable press release news feed in the world

See more
  • AbCellera to Participate at Upcoming Investor Conferences in March

    AbCellera (NASDAQ:ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health Care Conference, March 3-5 KeyBanc Capital Markets Healthcare Forum, March 18-19 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is f

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

    AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, da

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

    AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE:ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera's TCE platform to develop therapeutic antibodies for tumor targets. "We are pleased to broaden our AbbVie collaboration and look forward to using AbCellera's TCE platform to bring novel cancer immunotherapies to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and

    $ABBV
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Pharmaceuticals and Biotechnology

$ABCL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ABCL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ABCL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ABCL
SEC Filings

See more

$ABCL
Leadership Updates

Live Leadership Updates

See more
  • AbCellera Announces Resignation of Board Member

    AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

    TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • AbCellera Announces Changes to Its Board of Directors

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

$ABCL
Financials

Live finance-specific insights

See more
  • AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

    AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, da

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • AbCellera Reports Q3 2024 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
  • AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

    AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

$ABCL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more